Wang Jin, Teng Fei
Department of Traditional Chinese Medicine, The People's Hospital of Pizhou, Pizhou, China.
Department of Orthopedic, The People's Hospital of Pizhou, Pizhou, China.
Front Med (Lausanne). 2025 Jul 25;12:1620264. doi: 10.3389/fmed.2025.1620264. eCollection 2025.
Current evidence from randomized controlled trials (RCTs) supports the anti-osteoporotic properties of Chinese Herbal Medicine (CHM); however, its therapeutic advantages over conventional treatments remain inconclusive. This study aimed to compare the therapeutic effects of CHM with those of conventional therapy in patients with osteoporosis, using a meta-analysis approach.
A systematic search of PubMed, Embase, Cochrane Library, CNKI, and Wanfang databases was conducted through March 2025 to identify eligible RCTs. The weighted mean difference (WMD) and 95% confidence intervals (CI) were used as effect estimates, with pooled analyses calculated using a random-effects model. Additional exploratory analyses included sensitivity and subgroup analyses.
Eighteen RCTs involving a total of 1,816 patients with osteoporosis were included in the meta-analysis. CHM was associated with increased bone mineral density (BMD) at the lumbar spine (WMD: 0.09; 95% CI: 0.04 to 0.13; < 0.001), femoral neck (WMD: 0.09; 95% CI: 0.02 to 0.17; = 0.015), and Ward's triangle area (WMD: 0.08; 95% CI: 0.01 to 0.15; = 0.025). However, CHM showed no significant effect on BMD at the greater trochanter of the femur (WMD: 0.01; 95% CI: -0.03 to 0.05; = 0.698). Additionally, CHM was not associated with changes in alkaline phosphatase (WMD: 0.98; 95% CI: -6.88 to 8.83; = 0.808), serum calcium (WMD: 0.08; 95% CI: -0.09 to 0.25; = 0.372), or serum phosphorus (WMD: -0.05; 95% CI: -0.22 to 0.12; = 0.574).
Chinese Herbal Medicine was associated with significant improvements in BMD at the lumbar spine, femoral neck, and Ward's triangle area compared to conventional therapies, though the evidence is limited by moderate study quality and high heterogeneity. The findings suggest potential benefits of CHM in specific skeletal sites, but further rigorous trials are needed to confirm efficacy.
INPLASY platform (number: INPLASY202530115).
随机对照试验（RCT）的现有证据支持中药的抗骨质疏松特性；然而，其相对于传统治疗的治疗优势仍不明确。本研究旨在采用荟萃分析方法比较中药与传统疗法对骨质疏松症患者的治疗效果。
通过对PubMed、Embase、Cochrane图书馆、中国知网和万方数据库进行系统检索，截至2025年3月，以确定符合条件的随机对照试验。加权平均差（WMD）和95%置信区间（CI）用作效应估计值，采用随机效应模型进行汇总分析。额外的探索性分析包括敏感性分析和亚组分析。
荟萃分析纳入了18项随机对照试验，共1816例骨质疏松症患者。中药与腰椎骨密度（BMD）增加相关（WMD：0.09；95%CI：0.04至0.13；P<0.001）、股骨颈（WMD：0.09；95%CI：0.02至0.17；P=0.015）和沃德三角区（WMD：0.08；95%CI：0.01至0.15；P=0.025）。然而，中药对股骨大转子处的骨密度无显著影响（WMD：0.01；95%CI：-0.03至0.05；P=0.698）。此外，中药与碱性磷酸酶变化（WMD：0.98；95%CI：-6.88至8.83；P=0.808）、血清钙（WMD：0.08；95%CI：-0.09至0.25；P=0.372）或血清磷（WMD：-0.05；95%CI：-0.22至0.12；P=0.574）无关。
与传统疗法相比，中药与腰椎、股骨颈和沃德三角区的骨密度显著改善相关，尽管证据受研究质量中等和异质性高的限制。研究结果表明中药在特定骨骼部位可能有益，但需要进一步严格试验来证实疗效。
INPLASY平台（编号：INPLASY202530115）
Zotero 插件
